Advances in Clinical and Experimental Medicine

Adv Clin Exp Med
Impact Factor (IF) – 1.514
Index Copernicus (ICV 2018) – 157.72
MNiSW – 40
Average rejection rate – 84.38%
ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 8, August, p. 1067–1071

doi: 10.17219/acem/103803

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Creative Commons BY-NC-ND 3.0 Open Access

Correlation of rs749292 and rs700518 polymorphisms in the aromatase gene (CYP19A1) with osteoporosis in postmenopausal Polish women

Adam Kamiński1,A,D,E, Anna Bogacz2,3,C,E, Małgorzata Górska-Paukszta2,B,C, Agnieszka Seremak-Mrozikiewicz4,5,A,E, Bogusław Czerny2,6,A,F

1 Department of Orthopedics and Traumatology, Independent Public Clinical Hospital No. 1, Pomeranian Medical University, Szczecin, Poland

2 Department of Stem Cells and Regenerative Medicine, Institute of Natural Fibers and Medicinal Plants, Plewiska, Poland

3 Department of Histocompatibility with Laboratory of Genetic Diagnostics, Regional Blood Center, Poznań, Poland

4 Division of Perinatology and Women’s Diseases, Poznan University of Medical Sciences, Poland

5 Department of Pharmacology and Phytochemistry, Institute of Natural Fibres and Medicinal Plants, Plewiska, Poland

6 Department of Pharmacology and Pharmacoeconomics, Pomeranian Medical University, Szczecin, Poland

Abstract

Material and Methods. The study included 675 unrelated women (109 women with osteopenia, 333 women with osteoporosis, and 233 healthy women). Genomic DNA was extracted from the blood samples and the CYP19A1 polymorphisms were determined using the polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) method. Bone mineral density at the lumbar spine (L1–L4) was measured with dual energy X-ray absorptiometry (DEXA).
Results. The analysis of the CYP19A1 rs749292 polymorphism showed that there were no statistically significant differences in the distribution of genotypes between the study groups with osteoporosis and osteopenia and the control group. However, it was noted that the GG genotype occurred more often in the group with osteopenia (35.8%; OR = 1.44) than in the control group (27.9%). Also, a difference was noted in the distribution of genotypes in women with osteoporosis. In addition, it can be assumed that the G allele may lead to an increased susceptibility to osteopenia and osteoporosis. The analysis of the CYP19A1 rs700518 polymorphism showed that heterozygotes were more common in the group with osteoporosis (58.3%) than in the control group (52.8%).
Conclusion. Our results suggest that the rs749292 polymorphism of the CYP19A1 gene may contribute to an elevated risk for fractures in postmenopausal Polish women.

Key words

postmenopausal osteoporosis, gene polymorphism, bone mineral density, CYP19A1

References (18)

  1. Lorentzon M, Swanson C, Eriksson AL, Mellström D, Ohlsson C. Polymorphisms in the aromatase gene predict areal BMD as a result of affected cortical bone size: The GOOD study. J Bone Miner Res. 2006;21(2):332–339.
  2. Carson JA, Manolagas SC. Effects of sex steroids on bones and muscles: Similarities, parallels, and putative interactions in health and disease. Bone. 2015;80:67–78.
  3. Riancho JA, Valero C, Naranjo A, Morales DJ, Sanudo C, Zarrabeitia MT. Identification of an aromatase haplotype that is associated with gene expression and postmenopausal osteoporosis. Clin Endocr Metab. 2007;92(2):660–665.
  4. Shimodaira M, Nakayama T, Sato N, et al. Association study of aromatase gene (CYP19A1) in essential hypertension. Int J Med Sci. 2008;5(1):29–35.
  5. Bulun SE, Sebastian S, Takayama K, Suzuki T, Sasano H, Shozu M. The human CYP19 (aromatase P450) gene: Update on physiologic roles and genomic organization of promoters. J Steroid Biochem Mol Biol. 2003;86(3–5):219–224.
  6. Leelawattana R, Ziambaras K, Roodman-Weiss J, et al. The oxidative metabolism of estradiol conditions postmenopausal bone density and bone loss. J Bone Miner Res. 2000;15(12):2513–2520.
  7. Masi L, Becherini L, Gennari L, et al. Polymorphism of the aromatase gene in postmenopausal Italian women: Distribution and correlation with bone mass and fracture risk. J Clin Endocrinol Metab. 2001;86(5):2263–2269.
  8. Somner J, McLellan S, Cheung J, et al. Polymorphisms in the P450 c17 (17-hydroxylase/17,20-Lyase) and P450 c19 (aromatase) genes: Association with serum sex steroid concentrations and bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 2004;89(1):344–351.
  9. Gennari L, Masi L, Merlotti D, et al. A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: Effects on bone metabolism. J Clin Endocrinol Metab. 2004;89(6):2803–2810.
  10. Riancho JA, Zarrabeitia MT, Valero C, et al. Aromatase gene and osteoporosis: Relationship of ten polymorphic loci with bone mineral density. Bone. 2005;36(5):917–925.
  11. Riancho JA, Sanudo C, Valero C, et al. Association of the aromatase gene alleles with BMD: Epidemiological and functional evidence. J Bone Miner Res. 2009;24(10):1709–1718.
  12. Zarrabeitia MT, Hernández JL, Valero C, et al. A common polymorphism in the 5’-untranslated region of the aromatase gene influences bone mass and fracture risk. Eur J Endocrinol. 2004;150(5):699–704.
  13. Tofteng CL, Kindmark A, Brändström H, et al; Danish Osteoporosis Prevention Study. Polymorphisms in the CYP19 and AR genes – relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy: The Danish Osteoporosis Prevention Study. Calcif Tissue Int. 2004;74(1):25–34.
  14. Napoli N, Rastelli A, Ma C, et al. Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer. Bone. 2013;55(2):309–314.
  15. Kopp TI, Jensen DM, Ravn-Haren G, et al. Alcohol-related breast cancer in postmenopausal women: Effect of CYP19A1, PPARG and PPARGC1A polymorphisms on female sex-hormone levels and interaction with alcohol consumption and NSAID usage in a nested case-control study and a randomized controlled trial. BMC Cancer. 2016;16:283.
  16. Flote VG, Furberg AS, McTiernan A, et al. Gene variations in estrogen pathways, CYP19A1, daily 17β-estradiol and mammographic density phenotypes in premenopausal women. Breast Cancer Res. 2014;16:499.
  17. Yilmaz MB, Pazarbasi A, Guzel AI, et al. Association of serum sex steroid levels and bone mineral density with CYP17 and CYP19 gene polymorphisms in postmenopausal women in Turkey. Genet Mol Res. 2011;10(3):1999–2008.
  18. Geng L, Yao ZW, Luo JY, Han LL, Lu Q. Association between Val80 polymorphism of the CYP19 gene, A163G polymorphism of the OPG gene and bone mineral density in post-menopausal Chinese women [in Chinese]. Yi Chuan. 2007;29(11):1345–1350.